Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8613769

— · F

4a53ce0f-e14a-5b56-81a5-ff001ec6cf82

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
F
subtype
F

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.470
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.450
  • INTERFERON_GAMMA_RESPONSE+0.440
  • ANDROGEN_RESPONSE+0.400
  • ALLOGRAFT_REJECTION+0.390
  • XENOBIOTIC_METABOLISM+0.380
  • FATTY_ACID_METABOLISM+0.360
  • BILE_ACID_METABOLISM+0.350
  • PROTEIN_SECRETION+0.280
  • IL6_JAK_STAT3_SIGNALING+0.270

Top 10 suppressed

  • E2F_TARGETS-0.530
  • MYC_TARGETS_V2-0.530
  • WNT_BETA_CATENIN_SIGNALING-0.480
  • G2M_CHECKPOINT-0.450
  • MYC_TARGETS_V1-0.410
  • MITOTIC_SPINDLE-0.340
  • HEDGEHOG_SIGNALING-0.320
  • ANGIOGENESIS-0.290
  • NOTCH_SIGNALING-0.250
  • SPERMATOGENESIS-0.210

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518368
breast-umap@18
—D0.859
2BS_AG3D3435
brain-umap@2
subependymal giant cell astrocytoma(SEGA)—0.857
3ERR2208891
melanoma-umap@29
——0.849
4SRR8518337
breast-umap@18
—F0.847
5TCGA-5N-A9KM-01A-11R-A42T-07
bladder-landscape@3
——0.845
6SJEPD031138_D2.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.836
7SRR11296843
colon-landscapes@1
——0.835
8TCGA-CV-6955-01A-11R-2016-07
head-neck@1
——0.832
9SRR6013535
lung-landscapes@6
—cohortMD20.827
10SRR8518388
breast-umap@18
—D0.826

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.470Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.450Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.440Idelalisib— uncovered
ANDROGEN_RESPONSE0.400Inavolisib— uncovered
ALLOGRAFT_REJECTION0.390Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.380Inavolisib— uncovered
FATTY_ACID_METABOLISM0.360Inavolisib— uncovered
BILE_ACID_METABOLISM0.350Inavolisib— uncovered
PROTEIN_SECRETION0.280Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.270Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.270Idelalisib— uncovered
ADIPOGENESIS0.260Inavolisib— uncovered
COMPLEMENT0.250Inavolisib— uncovered
IL2_STAT5_SIGNALING0.230Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.210Inavolisib— uncovered
MTORC1_SIGNALING0.190Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.190Inavolisib— uncovered
PEROXISOME0.170Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.160Inavolisib— uncovered
APICAL_SURFACE0.150Temsirolimus— uncovered